SMALL CELL LUNG CANCER

This study tests a combination of two drugs, QL1706 and anlotinib, for people with advanced small cell lung cancer who have already tried at least two prior treatments. The goal is to see if the combination helps control the cancer and extends survival. About 120 adults aged 18 t…

This Phase 3 trial will test whether a new drug called BL-M14D1 combined with atezolizumab works better than the current standard treatment for people with extensive-stage small cell lung cancer who have not had prior therapy. About 550 adults will be randomly assigned to receive…

This early-stage study tests a new drug called HH160 in about 56 adults with advanced solid tumors (cancers that have spread). The main goals are to check safety, find the best dose, and see if the drug shrinks tumors. Participants will receive HH160 alone or with other cancer tr…

This study tests an experimental drug called DXC006 combined with either an immunotherapy drug (toripalimab) or standard chemotherapy (carboplatin or cisplatin) in 200 people with small cell lung cancer. The goal is to find the safest dose and see if the combination shrinks tumor…

This phase 3 trial tests a new type of radiotherapy that uses daily MRI scans to precisely target brain metastases from lung cancer. The approach, called MR-guided adaptive radiotherapy, adjusts the radiation dose based on real-time tumor changes. Researchers hope it will improve…

This phase 2 trial tests a drug called FHD-286 in 20 people with a specific type of small-cell lung cancer that has a marker called POU2F3. Participants take the drug by mouth once daily in 21-day cycles. The main goal is to see if the drug can shrink tumors.

This study tests a drug called tarlatamab in 35 adults with small cell lung cancer that has spread to the brain but is not causing symptoms. The goal is to see if the drug can shrink or control these brain tumors. Participants must have already had standard chemotherapy and be in…

This early-phase study tests whether adding an experimental drug (DSP-0390) to the immunotherapy atezolizumab can safely help prevent extensive stage small cell lung cancer from growing back after initial chemotherapy and immunotherapy. About 20 adults whose cancer did not worsen…

This phase 2 trial tests a combination of nab-paclitaxel (a chemotherapy drug) and local radiation therapy for people with extensive-stage small-cell lung cancer whose disease has worsened after initial treatment. The study aims to see if this combo can improve progression-free s…

This early study tests a new drug (177Lu-DTPA-SC16.56) that delivers radiation directly to cancer cells in people with small-cell lung cancer or neuroendocrine prostate cancer that has come back after standard chemotherapy. The main goal is to find the safest dose and see if the …

This Phase 2 trial tests a combination of two drugs, utidelone and bevacizumab, with or without a third drug called etoposide, in 56 patients with brain metastases from lung or breast cancer. The goal is to see if this treatment can shrink brain tumors and improve outcomes. Parti…

This study tests a combination of the targeted drug limertinib plus chemotherapy (etoposide and carboplatin) in 30 people with a specific type of lung cancer. These patients have a mutation in the EGFR gene and their cancer has changed from non-small cell to small cell lung cance…

This early-phase study tests a new drug called SYS6090 combined with standard chemotherapy or other drugs in about 600 people with advanced lung cancer (non-small cell or small cell). The goal is to see if the combinations are safe and if they can shrink tumors. The trial is not …

This study tests a combination of two drugs (adebrelimab and oral etoposide) in elderly or frail patients with small cell lung cancer. The goal is to see if this treatment can slow down the cancer's growth and improve outcomes. About 47 participants will receive the treatment, an…

This phase 2 trial tests a four-drug maintenance therapy for people with extensive small cell lung cancer that has responded to initial treatment. The combination includes liposome irinotecan, platinum chemotherapy, an immune checkpoint inhibitor (toripalimab), and an anti-angiog…

This study tests a new drug, ABBV-706, against standard treatments for small cell lung cancer that has come back or stopped responding. About 531 adults will receive either ABBV-706 or usual care (topotecan, lurbinectedin, or amrubicin) to see which works better. The goal is to s…

This study tests an experimental oral drug called XNW34017 in 150 people with advanced solid tumors who have not responded to or cannot tolerate standard treatments. The trial has two parts: first, finding a safe dose, then expanding to see if the drug can shrink tumors. It is an…

This phase 2 trial tests the drug golidocitinib in 16 people with advanced lung cancer who have severe blood problems caused by immunotherapy. The goal is to see if the drug can safely improve blood counts and reduce symptoms. Participants take the drug until their blood levels r…

This study tests a new drug called TYK-01054 for people with advanced solid tumors that have not responded to standard treatments. The drug is taken as a capsule and works by blocking a protein (TEAD) involved in cancer growth. The trial will check safety, find the best dose, and…

This phase 2 trial tests a combination of two drugs—HLX43 and serplulimab—in 120 people with advanced lung cancer (non-small cell or small cell). The goal is to see if the combo can shrink tumors and control the disease. Participants must have cancer that has spread or come back …

This study looks at whether the shingles vaccine can prevent shingles and improve survival in 500 lung cancer patients. Participants will either receive the vaccine or not, and researchers will track shingles cases and survival rates over time. The goal is to see if the vaccine o…

This study tests whether a home-based exercise program can help people with gastrointestinal or lung cancer handle chemotherapy better. Up to 120 participants will be randomly assigned to either an aerobic and resistance exercise group or a stretching group. All activities are do…

This study uses blood tests (liquid biopsies) to track how small cell lung cancer changes during chemotherapy and immunotherapy. Researchers will analyze DNA from blood samples taken before, during, and after treatment in 50 patients. The goal is to understand why some cancers be…

This study will collect blood samples from 25 people with small cell lung cancer who are being treated with the drug tarlatamab. Researchers will analyze the samples to learn more about how the drug works, who might benefit most, and how to predict side effects like cytokine rele…

This study collects blood and tissue samples from 110 adults with advanced lung, head and neck, or mesothelioma cancer. The samples are stored in a biobank to help scientists study cancer genes and find better ways to predict treatment outcomes. Participants do not receive any ex…

This study looks back at medical records of 200 adults in Latin America with a rare and aggressive cancer called neuroendocrine carcinoma. Researchers want to understand how patients are diagnosed, what treatments they receive, and how their disease progresses over time. The goal…

This study will observe 300 people with advanced lung or gastrointestinal cancers who receive adebrelimab combined with other treatments. Researchers will track side effects and how well the cancer responds. It is a real-world study, meaning it watches what happens in regular med…

This study will follow 96 adults with extensive-stage small cell lung cancer to see how they are treated in everyday hospital settings and how they respond. Doctors will choose treatments as usual, and researchers will collect data from medical records and regular check-ins every…